Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02552953
Recruitment Status : Recruiting
First Posted : September 17, 2015
Last Update Posted : August 21, 2019
Sponsor:
Information provided by (Responsible Party):
Cyclacel Pharmaceuticals, Inc.

Brief Summary:
This is an open-label, single arm, dose escalation study in patients with advanced cancers.

Condition or disease Intervention/treatment Phase
Cancer Drug: CYC065 Phase 1

Detailed Description:
This is an open-label, single arm, dose escalation study in patients with advanced cancers. Treatment will be administered on an outpatient basis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Actual Study Start Date : September 2015
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : March 2021

Arm Intervention/treatment
Experimental: CYC065
CYC065 will be administered every 3 weeks.
Drug: CYC065



Primary Outcome Measures :
  1. Number of patients who experience dose-limiting toxicities [ Time Frame: cycle 1(each cycle is 28 days) ]

Secondary Outcome Measures :
  1. Plasma concentrations [ Time Frame: cycle 1(each cycle is 28 days) ]
  2. Half-life of CYC065 [ Time Frame: cycle 1(each cycle is 28 days) ]
  3. changes in certain protein levels in peripheral white blood cells by western blots [ Time Frame: cycle 1(each cycle is 28 days) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed solid tumors or lymphomas that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
  • 18 years or older
  • ECOG performance status 0-1
  • Life expectancy ≥ 3 months
  • Evaluable disease
  • Adequate organ functions
  • 4 weeks from prior chemotherapy ( 6 weeks for mitomycin C and nitrosourea) , immunotherapy, investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities
  • At least 4 weeks from major surgery
  • Agree to practice effective contraception
  • Agree to follow protocol required evaluations
  • Ability to understand and willingness to sign the informed consent form

Exclusion Criteria:

  • Previously untreated CNS metastasis or progressive CNS metastasis
  • Currently receiving radiotherapy, biological therapy, or any other investigational agents
  • Uncontrolled intercurrent illness
  • Pregnant or lactating women
  • Known to be HIV-positive
  • Known active hepatitis B and/or hepatitis C infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02552953


Contacts
Layout table for location contacts
Contact: Judy Chiao, MD 908-517-7330

Locations
Layout table for location information
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Geoffrey Shapiro, MD         
Contact: Andrew Wolanski, NP    617.632.6623    Andrew_wolanski@dfci.harvard.edu   
Sponsors and Collaborators
Cyclacel Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Geoffrey Shapiro, MD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Cyclacel Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02552953     History of Changes
Other Study ID Numbers: CYC065-01
First Posted: September 17, 2015    Key Record Dates
Last Update Posted: August 21, 2019
Last Verified: October 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Adenosine
Cyclin-Dependent Kinase Inhibitor Proteins
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents